Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15155
Abstract: e15155Background: High-dose (HD) IL-2 is approved for patients with melanoma and renal cell carcinoma but is associated with significant toxicity, given only in an inpatient setting. RO6874281 is a...
read more here.
Keywords:
tumor activity;
safety anti;
anti tumor;
ro6874281 engineered ... See more keywords